Copenhagen University is now offering a Master on Headache Disorders. It´s a continuing professional development programme for healthcare professionals. The programme requires a minimum of 6 individual visits to Copenhagen, Denmark over a two-year period: Modules 1 to 4 are organized with an e-learning self-study period followed by one week of face-to-face sessions at University of Copenhagen. Module 5 is a three week clinical course at the Danish Headache Centre. Module 6 is the final module. This module is comprised of a master’s thesis, which is completed with an oral examination in Denmark. This medical master’s programme consists of modules covering headache [...]
INDIANAPOLIS, Sept. 21, 2018 Lilly Receives Positive CHMP Opinion for EmgalityTM (galcanezumab) for the Prophylaxis of Migraine in Adults Eli Lilly and Company announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Emgality TM (galcanezumab) for the prophylaxis of migraine in adults who have at least four migraine days per month. TM In June 2018, Lilly announced the intended brand name, Emgality, was conditionally accepted by the U.S. Food and Drug Administration (FDA). Emgality is a humanized monoclonal antibody specifically designed to bind to the calcitonin gene-related peptide (CGRP), blocking its [...]
Active Citizenship Network launch the second edition of the bi-annual research-project at the European level “EU Civic Prize on Chronic Pain - Collection of good practices” with the aim to continue to give evidence on existing good practices in several European countries in terms of the struggle against pain. Aims of the project Giving continuity to the successful collection of good practices “EU Civic Prize on Chronic Pain - Collection of good practices” - First Edition. Enriching European and national experiences, expertise, data and benchmarking on chronic pain. Fostering the multi-stakeholder platform of operators of good practices on pain, created in [...]
How can this even be a trend!!!!???? Headache Pose? Migraine Pose? What is this supposed to mean? Migraine is not a pose but a neurological disorder involving nerve pathways and brain chemicals, which leaves completely disabled anyone who suffers an attack for an uncertain period of time. It´s very sad and outrageous that such an important magazine like ELLE.com publishes an article which undermines the real importance of such a severe condition. We were shocked when we saw this and thought how relevant it was to share it, this publication does no other thing rather than increasing the stigma of migraine. The images [...]
EMHA Executive Director Mrs. Elena Ruiz de la Torre flew the past month of August to Zurich in order to attend the first European Patient Advocacy Council F2F meeting where the topics for discussion were: 1. “Addressing inequalities in the patient voice across Europe”. 2. “Demonstrating the Impact of Patient Engagement”.
The past September 6th the European Migraine and Headache Alliance team flew all the way to London to assist to the 17th Biennial Migraine Trust International Symposium. It was an amazing and exciting event full of people interested in finding ways to give a brighter future to migraineurs. We were beyond than an honor to be part of this symposium and represent the patients' community in such an important Congress. You can find below some images of what we lived last week, already looking forward to the next MTIS!
Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its- kind treatment specifically designed for migraine prevention Jul 30, 2018 Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month. Aimovig is the first and only treatment specifically designed for migraine prevention to be approved in the European Union, Switzerland, the US and Australia. It works by blocking a receptor called the calcitonin gene-related peptide receptor (CGRP-R) which plays a critical role in mediating the incapacitating pain of migraine. [...]
Very common especially in women, these intense headaches are still a great medical mystery whose causes are not enlightened. Very common especially in women, these intense headaches are still a great medical mystery whose causes are not enlightened. Migraines are always related to a "simple headache", but they are much more. While "normal" headaches can be controlled with a paracetamol or two, a migraine is way more aggressive, sometimes so much severe that it can weaken the physical and mental capacities of the sufferer, as well as affect his day a day. The most mysterious thing is that it does not [...]
The journal Cephalalgia – the scientific publication of the International Society of Headaches – has just published a study by members of the Headache Study Group of the Spanish Society of Neurology (SEN) of the Vall D'Hebron University Hospital, whose Objective was to evaluate the prevalence of a headache among the Spanish adolescent population. Carried out among more than 1,500 students aged between 12 and 18 and belonging to several institutes in Catalonia, the study also sought to analyze the most frequent types of headache in this population group as well as the relationship of their headaches with comorbidities and [...]
30 DE MAYO DE 2018 If we pay attention to what we eat, we can contribute to keeping headaches as far away from our lives as possible. If you have migraines, you probably know that maintaining a healthy lifestyle and respecting food and sleep schedules are two fundamental elements to keep them under control. But there is a third element we have that we cannot neglect, our nourishment. And it is that what we eat seems to be, in a large number of cases, closely related to certain headaches. Beware of amines Amines (Histamines, Tiraminas...) are substances present in many [...]